Skip to main content
SpringerLink
Log in

Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms

  • Chapter
  • First Online:
Onko-Nephrologie

  • 648 Accesses

Zusammenfassung

Nierenzellkarzinome (NZK) machen 2–4 % der malignen Neoplasien im Erwachsenenalter aus. Bei Diagnosestellung liegt häufig ein lokalisiertes Stadium vor. Liegt ein metastasiertes NZK vor, das einer Lokaltherapie nicht zugänglich ist, rücken medikamentöse Verfahren in den Vordergrund. Durch zahlreiche Neuzulassungen hat sich die Therapielandschaft hierbei in den vergangenen Jahren grundlegend gewandelt. Neben der zielgerichteten Therapie mit Tyrosinkinase-Inhibitoren werden Immuncheckpoint-Inhibitoren sowie Kombinationstherapien aus beiden Substanzgruppen eingesetzt. Beide Behandlungsformen gehen auch weiterhin mit einer hohen Rate an Nebenwirkungen einher. Diese lassen sich durch ein gut abgestimmtes Nebenwirkungsmanagement in der Regel gut behandeln. Der Artikel gibt einen Überblick über gängige Klassifikationssysteme sowie aktuelle medikamentöse Behandlungsstrategien für das NZK.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Appleman, L. J. (2019). Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). S. K. P. aneka Puligandla, Wayne Harris, Neeraj Agarwal, Brian Addis Costello, Christopher W. Ryan, Michael Pins, J Clin Oncol. Suppl abstract (4502).

    Google Scholar 

  • Behrens G, Leitzmann MF (2013) The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer 108(4):798–811

    Article  CAS  Google Scholar 

  • Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C, Russo P (2019) Epidemiology of renal cell carcinoma. Eur Urol 75(1):74–84

    Article  Google Scholar 

  • Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, M Investigators (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1814–1823

    Article  CAS  Google Scholar 

  • Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 35(6):591–597

    Article  CAS  Google Scholar 

  • Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer 94:115–125

    Article  CAS  Google Scholar 

  • Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A, E G Committee (2019) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(5):706–720

    Article  CAS  Google Scholar 

  • Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356–387

    Article  CAS  Google Scholar 

  • Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6):2395–2400

    Article  Google Scholar 

  • Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC (2001) Family history and risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 10(9):1001–1004

    CAS  PubMed  Google Scholar 

  • Gospodarowicz M (2017) TNM classification of malignant tumors. UICC International Union Against Cancer. Wiley-Blackwell, New Jersey, S 199

    Google Scholar 

  • Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI (2018) Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 29(12):2371–2378

    Article  CAS  Google Scholar 

  • Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM (2014) The role of HIF1α in renal cell carcinoma tumorigenesis. J Mol Med (Berl) 92(8):825–836

    Article  CAS  Google Scholar 

  • Guo H, German P, Bai S, Barnes S, Guo W, Qi X, Lou H, Liang J, Jonasch E, Mills GB, Ding Z (2015) The PI3K/AKT pathway and renal cell carcinoma. J Genet Genomics 42(7):343–353

    Article  Google Scholar 

  • Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, E G Committee (2018) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(4):iv264–iv266

    Article  CAS  Google Scholar 

  • Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016

    Article  CAS  Google Scholar 

  • Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK (2013) External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148

    Article  Google Scholar 

  • Moch H (2016) The WHO/ISUP grading system for renal carcinoma. Pathologe 37(4):355–360

    Article  CAS  Google Scholar 

  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540

    Article  CAS  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  CAS  Google Scholar 

  • Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013a) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731

    Article  CAS  Google Scholar 

  • Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE (2013b) Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31(30):3791–3799

    Article  CAS  Google Scholar 

  • Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, C Investigators (2015a) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813

    Article  CAS  Google Scholar 

  • Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015b) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473–1482

    Article  CAS  Google Scholar 

  • Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN, P Investigators (2017) Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35(35):3916–3923

    Article  CAS  Google Scholar 

  • Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, C Investigators (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290

    Article  CAS  Google Scholar 

  • Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115

    Article  CAS  Google Scholar 

  • Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ, S-T Investigators (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375(23):2246–2254

    Article  CAS  Google Scholar 

  • Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939

    Article  CAS  Google Scholar 

  • Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, K Investigators (2019a) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127

    Article  CAS  Google Scholar 

  • Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ, I S Group (2019b) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393(10189):2404–2415

    Article  Google Scholar 

  • Robert-Koch-Institut (2016) Bericht zum Krebsgeschehen in Deutschland 2016

    Google Scholar 

  • Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49(6):1287–1296

    Article  CAS  Google Scholar 

  • Tahbaz R, Schmid M, Merseburger AS (2018) Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol 28(1):62–79

    Article  Google Scholar 

  • Tsuzuki T, Iwata H, Murase Y, Takahara T, Ohashi A (2018) Renal tumors in end-stage renal disease: a comprehensive review. Int J Urol 25(9):780–786

    Article  Google Scholar 

  • Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Tocchetti CG (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2(4):e000247

    Article  Google Scholar 

  • Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 5(7):1008–1019

    Article  Google Scholar 

  • Warren AY, Harrison D (2018) WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World J Urol 36(12):1913–1926

    Article  Google Scholar 

  • Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20(23):4559–4566

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Susanne Delecluse

  2. Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Stefanie Zschäbitz

Authors
  1. Susanne Delecluse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefanie Zschäbitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Delecluse .

Editor information

Editors and Affiliations

  1. Nationales Zentrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Dirk Jäger

  2. Nephrologie, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Martin Zeier

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Delecluse, S., Zschäbitz, S. (2020). Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms. In: Jäger, D., Zeier, M. (eds) Onko-Nephrologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59911-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59911-2_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59910-5

  • Online ISBN: 978-3-662-59911-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation